eFinder

eFinder

LENIAS HWENDA | Drive to make HIV-prevention shot in SA could reshape industry

Fact-Check Results

“The resurgence of 'America First' industrial policy is reshaping global supply chains”
INSUFFICIENT EVIDENCE — No relevant evidence found in archive to confirm or refute the claim about global supply chain reshaping by 'America First' policy.
“Countries are treating pharmaceutical production as a strategic capability”
INSUFFICIENT EVIDENCE — No evidence in archive to verify whether countries treat pharmaceutical production as a strategic capability.
“South Africa has about 7.8-million people living with HIV”
INSUFFICIENT EVIDENCE — No data in archive to confirm South Africa's HIV prevalence figures.
“About 170,000 new infections are recorded annually in South Africa”
INSUFFICIENT EVIDENCE — No evidence in archive to verify annual HIV infection rates in South Africa.
“South Africa is attempting to position itself as a manufacturer of lenacapavir”
INSUFFICIENT EVIDENCE — No information in archive about South Africa's efforts to manufacture lenacapavir.
“Lenacapavir is developed by Gilead Sciences”
INSUFFICIENT EVIDENCE — No evidence in archive to confirm lenacapavir's development by Gilead Sciences.
“The medicine can be administered as an injection just twice a year”
INSUFFICIENT EVIDENCE — No data in archive to verify lenacapavir's administration method.
“Daily adherence has long been one of the biggest obstacles to effective prevention programmes”
INSUFFICIENT EVIDENCE — No evidence in archive to confirm historical challenges with daily adherence to HIV prevention programs.
“South Africa imports 60%-70% of its finished medicines”
INSUFFICIENT EVIDENCE — No information in archive about South Africa's pharmaceutical imports.
“The pharmaceutical trade deficit exceeds R30bn a year”
INSUFFICIENT EVIDENCE — No evidence in archive to verify South Africa's pharmaceutical trade deficit figures.
“A phased approach involves importing the active ingredient while doing local formulation and packaging”
PENDING
“South Africa runs one of the world's largest HIV treatment programmes”
PENDING
“Advanced pharmaceutical production requires specialised skills including chemical engineers and regulatory experts”
PENDING
“The main barrier was technical capacity, particularly the ability to manufacture the active pharmaceutical ingredient”
PENDING
“South African companies submitted bids to manufacture lenacapavir in an earlier licensing round”
PENDING
“Long-acting formulations represent one of the fastest-growing areas of pharmaceutical innovation”
PENDING
“Producing lenacapavir at scale demands sophisticated facilities and strict regulatory oversight”
PENDING
“South Africa's pharmaceutical market is worth about R70bn a year”
PENDING
“The Covid-19 pandemic exposed the risks embedded in the current model”
PENDING
“SANAC is coordinating a renewed effort to identify a local manufacturer for lenacapavir”
PENDING
“Eva Pharma in Egypt has been granted a licence to produce lenacapavir”
PENDING